González Rivas L, Sánchez Gómez E, Sánchez del Moral R, Grutzmancher Saiz S, Pujol de la Llave E, Bocanegra Martín C
Servicio de Farmacia, Hospital General de Especialidades Juan Ramón Jiménez, Huelva, España.
Farm Hosp. 2011 Nov-Dec;35(6):317-21. doi: 10.1016/j.farma.2011.01.003. Epub 2011 Oct 21.
To describe the efficacy, safety, compliance and cost savings of lopinavir/ritonavir monotherapy.
Observational, descriptive and retrospective study evaluating monotherapy. Adherence was calculated using an objective method. We estimated the direct costs of dispensing non-triple therapy.
We identified 17 patients. Interval adherence was > 95% in 9 patients, 90-95% in 2 patients, 90-85% in 2 patients, and less than 85% in 4 patients. Viral load was undetectable during weeks 12, 24, 36 and 48, except in 2 patients. The CD4 count in most analytical tests remained at > 350 cells/ml, only 1 patient had a lower figure. The average savings was 4819 Euros/patient/year (range 1116 to 8700).
In selected patients, monotherapy can be a cost-effective treatment option.
描述洛匹那韦/利托那韦单药治疗的疗效、安全性、依从性及成本节约情况。
对单药治疗进行观察性、描述性和回顾性研究。采用客观方法计算依从性。我们估算了非三联疗法的配药直接成本。
我们纳入了17例患者。9例患者的间期依从性>95%，2例患者为90 - 95%，2例患者为90 - 85%，4例患者低于85%。除2例患者外，在第12、24、36和48周时病毒载量均检测不到。大多数分析检测中的CD4细胞计数保持在>350个细胞/毫升，只有1例患者数值较低。平均节约成本为4819欧元/患者/年（范围为1116至8700欧元）。
在选定的患者中，单药治疗可能是一种具有成本效益的治疗选择。
